ABSTRACT
The advent of the megatrial in cardiology has led to the development of important therapies to reduce mortality and morbidity from myocardial infarction and other acute coronary syndromes. This chapter summarizes the methodology that has laid the groundwork for the landmark trials in the field. The most important developments in the field of ACS have emerged from large simple trials (LSTs) that were specifically designed and powered to assess moderate differences in mortality (1).
